Lung adenocarcinoma (LUAD) is one of the most common causes of cancer death worldwide. Epidermal growth factor receptor (EGFR) mutations (MT) frequently target LUAD patients in Eastern Asia. EGFR tyrosine kinase inhibitors were developed to benefit LUAD patients harboring EGFR-activating MT. Unfortunately, biomarkers for early diagnosis and targeted therapy for patients with wild-type (WT) EGFR are currently lacking. Based on the super-SILAC, this study established a LUAD proteomics data set related to stage and EGFR status. Specifically, proteins obtained from three locally established LUAD cell lines were pooled with LUAD tissues from women, never smokers, different histological stages (early and late), and EGFR status (wild-type and mutant) to establish a quantitative proteome data set. We integrated genomic datasets and proteomic resources to select marker candidates for further characterization via immunohistochemistry and ELISA assays. The biological significance of marker candidates was examined using cell lines. This study provides new insights into the diagnosis and tumorigenesis of LUAD with EGFR-WT.